Guggenheim downgrades Acadia Pharmaceuticals to Neutral

Guggenheim Downgrades ACADIA Pharmaceuticals (ACAD)
Fintel reports that on January 3, 2025, Guggenheim downgraded their outlook for ACADIA Pharmaceuticals (NasdaqGS:ACAD) from Buy to Neutral. Analyst Price Forecast Suggests 37.23% Upside As of December 23,
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap Down – Here’s What Happened
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $18.66, but opened at $18.25. ACADIA Pharmaceuticals shares last traded at $18.
Guggenheim downgrades Acadia Pharmaceuticals to Neutral on lack of catalysts
As previously reported, Guggenheim downgraded Acadia Pharmaceuticals (ACAD) to Neutral from Buy with a price target of $20, down from $23. The
Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing
We recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other firms end 2024 stronger with impressive gains.
ACADIA Pharmaceuticals (NASDAQ:ACAD) Downgraded to Neutral Rating by Guggenheim
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) was downgraded by Guggenheim from a “buy” rating to a “neutral” rating in a research note issued on Friday,Briefing.com Automated Import reports.
ACADIA Pharmaceuticals Inc (ACAD) Stock Sees Market Value Hit $3.05 billion: What Are the Implications?
ACADIA Pharmaceuticals Inc (ACAD) stock saw a modest uptick, ending the day at $18.35 which represents a slight increase of $1.66 or 9.95% from the prior close of $16.69. The stock opened at $18.24 and touched a low of $17.
Acadia Pharmaceuticals downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Yatin Suneja downgraded Acadia Pharmaceuticals (ACAD) to Neutral from Buy with a $20 price target Discover the latest stocks recommended by top Wall Street analysts, all in one ...
Money Morning6d
Acadia Pharmaceuticals Soars 9% on S&P 600 Addition, Don't Buy the Stock!
Acadia’s 50-day moving average is in the process of crossing above the stock’s 200-day moving average. This crossover forms a ...
bovnews17h
What Factors Have Led to ACADIA Pharmaceuticals Inc (ACAD) Stock Trading -40.80% Below Its 52-Week High?
Guggenheim has recently reduced ACADIA Pharmaceuticals Inc (ACAD) stock to Neutral rating, as announced on January 3, 2025, according to Finviz. Earlier, on October 10, 2024, Raymond James had resumed ...
Acadia Pharmaceuticals Shares Rise With Co to Join S&P SmallCap 600
Shares of Acadia Pharmaceuticals rose after the company said it was set to join the S&P SmallCap 600 index. The biopharmaceutical company's stock jumped 12% to $18.73 in morning trading Tuesday, ...
Yahoo Finance7d
Acadia Pharmaceuticals Set to Join S&P SmallCap 600
NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of ...
bovnews6d
What’s Driving Acadia’s (ACAD) Stock to New Heights? The Surprising Reason Revealed!
The primary catalyst for Acadia Pharmaceuticals’ recent stock movement is its inclusion in the S&P SmallCap 600 Index. Starting January 3, 2025, Acadia will replace Independent Bank Group Inc. (NASDAQ ...